In gastric cancer, Yang et al. demonstrated that TGFβ2 played a vital role in linking epithelial–mesenchymal transition and tumor mutational burden, which suggested that TGFβ2 may be a predictive therapeutic target for GC [48]. Here, TGFB2 is linked to neoplasm.